The landmark legalization of cannabis in Germany, highlighted by
Investor's Business Daily, heralds a transformative era in the
European market, ushering in unparalleled opportunities for
forward-thinking companies like Endexx Corporation. Endexx is
strategically positioned to capitalize on its expertise in
plant-based active compounds, including cutting-edge cannabis
services, formulations, and delivery technologies, to cater to the
burgeoning demand across Europe.
Claude Zydnow, a distinguished Endexx Corporation Board member,
expressed enthusiasm about the European legislative shifts,
particularly in Germany, stating, "These legislative changes in
Europe, especially Germany, present a wealth of opportunities for
our innovative plant-based and vape product lines. We are eager to
expand our reach, introducing our proprietary formulations and
superior-quality products to new markets, capitalizing on the
global shift towards cannabis acceptance and the surging demand for
wellness products."
The HYLA division of Endexx is already making significant
strides, offering an exclusive array of all-natural, zero-nicotine
vape products that have garnered substantial traction across
diverse international markets, including the Middle East and
Europe. Recent distribution agreements with Sahara Trading in the
UAE and strategic partnerships in Italy with XVI Ventures have
primed HYLA for exponential growth and extended market
penetration.
Moreover, Endexx Corporation has commenced TPD registration in
Europe, further cementing its market presence and paving the way
for expanded distribution throughout the continent.
With a commitment to sustainability, wellness, and innovation,
Endexx Corporation invests in research and development, strategic
marketing, and global expansion efforts to leverage evolving market
dynamics and regulatory landscapes. The company's proactive stance
in embracing regulatory changes and exploring new market
opportunities is poised to drive substantial growth and generate
significant value for its shareholders in the years ahead.
About Endexx Corporation
Endexx Corporation develops and distributes all-natural,
plant-derived wellness and topical skincare products. Its products
vary from balms, creams, lotions, butter, masks, scrubs, and oils,
all with the shared purpose of healthy skin and grooming wellness.
The science behind these products involves a decade of clinical
research and lab work to provide a functional formulation with
ingredients for optimal absorption and skin health
support. www.endexx.com
About HYLA
Hyla currently markets its proprietary non-nicotine, guarana,
and L-Dopa-based vape products in a wide variety of flavors. The
Hyla device is the first non-nicotine vape product to be produced
in this manner in the United States and provides an unprecedented
4,500 puffs per device. Hyla is currently being distributed in 10
countries and has signed distribution agreements with an additional
nine countries. www.tryhyla.com
Safe Harbor Statement Under the Private Securities Litigation
Reform Act of 1995
This presentation may contain "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
1995, such as statements relating to financial results and plans
for future development activities. Forward-looking statements
include all statements that are not statements of historical fact
regarding intent, belief, or current expectations of the Company,
its directors, or its officers. Investors are cautioned that such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, many of which are beyond the
Company's control. Actual results may differ materially from those
projected in the forward-looking statements. Among the factors that
could cause actual results to differ materially from those
indicated in the forward-looking statements are risks and
uncertainties associated with the Company's business and finances
in general, including the ability to continue and manage its
growth, competition, global economic conditions, and other factors
discussed in detail in the Company's periodic filings with the
Securities and Exchange Commission. The Company undertakes no
obligation to update any forward-looking statements.
No Offer or Solicitation. This communication shall not
constitute an offer to sell or the solicitation of an offer to buy
any securities, nor shall there be any sale of securities in any
jurisdiction in which such offer, solicitation, or sale would be
unlawful before registration or qualification under the securities
laws of any such jurisdiction. No offering of securities shall be
made except utilizing a prospectus meeting the requirements of
Section 10 of the Securities Act of 1933, as amended, and, where
applicable, the requirements under the securities laws of any other
relevant jurisdiction.
For further details, please contact:
Endexx Corporation
IR@Endexx.com